chevron_leftBack
As of 5 June 2026, SillaJen, Inc. has a market cap of $322.61M USD, ranking #18169 globally and #588 in South Korea.
It ranks #1653 in the Healthcare sector, and #316 in the Biotechnology industry.
Key Stats
Market Cap
$322.61MUSD
494.5B KRW
Enterprise Value
$272.7MUSD
418.0B KRW
Revenue (TTM)
$6.02MUSD
9.23B KRW
EBITDA (TTM)
-$16.12MUSD
-24.71B KRW
Net Income (TTM)
-$15.78MUSD
-24.19B KRW
EBITDA Margin
-268%
Profit Margin
-262%
PS Ratio
53.6
PB Ratio
4.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Jaekyung Kim
open_in_new
Employees
57
Founded
2006
Website
sillajen.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.4% | -2.2% | -11% | -6.5% | 18% | -6.5% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
215600
신라젠(주)
ISIN: KR7215600008
Shares Out.:
Shares Outstanding:
138.554M1
Shares Float:
115.866M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
3,495 KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About SillaJen, Inc.
SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
KRX: 207940
|
$44.48B
14K%
68.19T KRW
|
35.5
|
|
KRX: 068270
|
$27.89B
9K%
42.76T KRW
|
43.8
|
|
KRX: 196170
|
$13.27B
4K%
20.33T KRW
|
146.6
|
|
KRX: 028300
|
$5.46B
2K%
8.37T KRW
|
-
|
|
KRX: 087010
|
$3.96B
1K%
6.07T KRW
|
-
|
|
KRX: 302440
|
$2.23B
593%
3.42T KRW
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
56K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
49K%
|
19.0
|
|
EBR: ARGX
|
$48.01B
15K%
41.39B EUR
|
39.9
|
|
ASX: CSL
|
$43.01B
13K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.55B
13K%
33.71B CHF
|
37.2
|
|
NASDAQ: NTRA
|
$27.6B
8K%
|
-
|
chevron_leftBack